Marie-Elisabeth Goebeler

Author

Also Known As

Marie-Elisabeth Goebeler

Publications

961

Citations

H-Index

Concepts

All Affiliations

Marie-Elisabeth Goebeler is an author at University Hospital Schleswig-Holstein specializing in cancer research, tumor immunity, and oncology.

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	54
2	Immunology	2	2	54
3	Health Sciences	1	1	18
4	Cellular Therapies	1	1	18
5	Pathology	1	1	18

Marie-Elisabeth Goebeler

Publications

953

Citations

H-Index

Page 1

	Year	Citations
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL Max S. Topp, Nicola Gökbuget, Gerhard Zugmaier, Blood	2012	466
Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma Andreas Viardot, Marie-Elisabeth Goebeler, Svenja Neumann, Blood	2016	358
Anti-CD19 BiTE Blinatumomab Induces High Complete Remission Rate and Prolongs Overall Survival in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL) Max S. Topp, Nicola Goekbuget, Gerhard Zugmaier, Blood	2012	43
A phase I study of EpCAM/CD3-bispecific antibody (MT110) in patients with advanced solid tumors. Walter Fiedler, M. Wolf, Maxim Kebenko, Journal of Clinical Oncology ImmunologyImmunoeditingImmunotherapeuticsT CellsAdvanced Solid Tumors	2012	36
Anti-CD19 BiTE Blinatumomab Induces High Complete Remission Rate In Adult Patients with Relapsed B-Precursor ALL: Updated Results of An Ongoing Phase II Trial Max S. Topp, Nicola Goekbuget, Gerhard Zugmaier, Blood	2011	32
Effect of anti-CD19 BiTE blinatumomab on complete remission rate and overall survival in adult patients with relapsed/refractory B-precursor ALL. Max S. Topp, Nicola Goekbuget, Gerhard Zugmaier, Journal of Clinical Oncology ImmunohematologyCell TherapyImmunologyPathologyImmunotherapy	2012	18

Page 1